Lyell Immunopharma, Inc. (LYEL) News
Filter LYEL News Items
LYEL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LYEL News Highlights
- LYEL's 30 day story count now stands at 2.
- Over the past 17 days, the trend for LYEL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about LYEL are LEE and GENE.
Latest LYEL News From Around the Web
Below are the latest news stories about Lyell Immunopharma Inc that investors may wish to consider to help them evaluate LYEL as an investment opportunity.
Biotech IPOs Have Slowed to a Snail's PaceDecline tied to falling stock prices of newly minted companies |
Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific OfficerSOUTH SAN FRANCISCO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced the appointment of Gary Lee, Ph.D., as Chief Scientific Officer. A veteran biotech leader with more than a decade of experience heading translational cell and gene therapy programs, Dr. Lee will set and oversee the company’s research strategy and advance its research pipeline |
Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSKSOUTH SAN FRANCISCO, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (NASDAQ: LYEL ), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, announced today that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for LYL132, an investigational T-cell receptor (TCR) therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 (NY-ESO-1) that the company is developing in collaboration with GSK. LYL132 incorporates Epi-R, Lyell''s epigenetic reprogramming technology and is under investigation as a potential next-generation enhancement to letetresgene autoleucel (lete-cel), a GSK TCR therapy targeting N... |
FDA Clears Lyell Immunopharma' LYL132 Trial For Solid TumorsThe FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in solid tumors. LYL132 is an investigational T-cell receptor (TCR) therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 (NY-ESO-1). LYL132 incorporates Epi-R, Lyell's epigenetic reprogramming technology, and is under investigation as a potential next-generation enhancement to letetresgene autoleucel (lete-cel), a |
Superstar biotech execs, scientists, funders launch $3 billion company to 'reverse disease'Backed by $3 billion and some of biotech's biggest names, Altos Labs officially emerged from stealth with the ambitious task of reversing disease. The company, which the San Francisco Business Times previously reported had leased space in Redwood City, will be led by former Genentech Inc. chief medical officer Hal Barron, who currently is president of research and development at GlaxoSmithKline plc and held the same position at aging disease research pioneer Calico. Rick Klausner, the former National Cancer Institute chief and founder of a handful of biotech companies, including South San Francisco's Lyell Immunopharma Inc. (NASDAQ: LYEL), is chief scientist, and Grail Inc. founder and former president Hans Bishop will be president. |
Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... |
Lyell Immunopharma (LYEL) Receives a Buy from Morgan StanleyIn a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Lyell Immunopharma (LYEL – Research Report), with a price target of $20.00. The company's shares closed last Thursday at $6.45. According to TipRanks.com, Harrison is a 5-star analyst with an average return of 11.8% and a 53.3% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Zentalis Pharmaceuticals, and BioMarin Pharmaceutical. The the analyst consensus on Lyell Immunopharma is currently a Moderate Buy rating. |
Lyell Immunopharma to Participate in 40th Annual J.P. Morgan Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (NASDAQ: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that members of its senior management team will participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, at 3:00 PM ET. During the conference, the Company will highlight its: Pipeline of CAR, TIL and TCR product candidates across multiple solid |
Lyell Immunopharma (NASDAQ:LYEL) Sees Unusually-High Trading VolumeShares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) saw unusually-high trading volume on Wednesday . Approximately 32,971 shares changed hands during mid-day trading, a decline of 93% from the previous sessions volume of 459,476 shares.The stock last traded at $7.65 and had previously closed at $7.40. The business has a 50-day moving average of $11.16. Lyell Immunopharma [] |
Is Now An Ideal Time To Purchase Lyell Immunopharma Inc. (NASDAQ: LYEL) Stock?Lyell Immunopharma Inc. (NASDAQ:LYEL) traded at $7.52 at close of the session on Monday, 12/20/21, made a downward move of -9.83% on its previous days price. Looking at the stock we see that its previous close was $8.34 with the days price range being $7.10 $8.385. In terms of its 52-week price range, LYEL Is Now An Ideal Time To Purchase Lyell Immunopharma Inc. (NASDAQ: LYEL) Stock? Read More » |